Comparative potentiality study of three different vero cell culture systems for production of PPR Vaccine

Gabr. F. El-Bagoury¹, Ehab. M. EL-Nahas¹, Lila Abdelazeem², Azza. M. Mohamed²

¹Department of virology, Faculty of Veterinary Medicine, Benha University
²Veterinary serum and vaccine Research institute, Abbasia, cairo.

A B S T R A C T

Peste des petits ruminants (PPR) is considered one of the most dangerous viral diseases of small ruminants in Africa and Asian countries. The disease control is based on vaccination of susceptible animals with an attenuated PPR virus strain (Nigeria 75/1) propagated in monolayers of Vero cells using stationery and roller flasks. This study for constructing alternative method for production of PPR vaccinal strain through propagation of PPR virus (75/l) on Vero cell culture supported on cytodex-three microcarrier beads using spinner stirring flasks and compare the recorded results with that obtained from stationary flasks (175cm²) and Roller Bottles. All cultures were propagated under the same conditions (media, pH, time of incubation) and infected with the same multiplicity of infection by PPR vaccinal virus. Samples were obtained daily for successive five days from all cultures. The PPR virus titers were 12 log₁₀ TCID₅₀, 5 log₁₀ TCID₅₀ and 6 log₁₀ TCID₅₀ on microcarriers culture, stationary system and roller system respectively after six days post infection. These results provide further insights to apply microcarriers cell culture technology in production of PPR vaccine.

Keywords: PPR, cytodex-3 microcarriers, spinner flasks, row bottles, roller bottles.

1. INTRODUCTION

Peste des petits ruminants (PPR) is an acute contagious viral disease caused by a virus within genus Morbillivirus, classified within family paramyxoviridae. (Gibbs et al, 1979). It affects small ruminants especially goats (OIE 2000), and occasionally wild animals (Furley et al., 1987). A homologous specific PPR attenuated vaccine is used in susceptible animals which is the best policy in control the disease (OIE, 2008). Like other Morbillivirus vaccines loss, it is titer during storage, transportation and after dissolving during animal vaccination in the ambient temperature (OIE, 1998).

Production of high titer of PPR virus in attenuated vaccine is considering a global aim to meet the demands of animal immunization campaigns, which reflect on eradication of PPR disease programs to fulfill requirement (OIE, 1998). Microcarriers beads have been extensively used in culture system to grow anchorage dependent mammalian cells to a high density in simple stirred flasks. Microcarriers were used for a variety of viruses on laboratories. Vero cells gown on cytodex3
microcarriers were used for propagation of poliovirus, (Duchene et al, 1999) Reovirus, (Butler et al ,2000) Rabies virus, (Rourou et al ,2007) Rinderpest virus (Uma and Bandyophayay, 1994) and PPR virus (Mohan et al, 2009). This study is considered as alternative way for PPR vaccine production with a high titer on micro carriers beads to meet the loss in virus titer during their shipment. So, we prevision for producing large quantities of vaccine in a short period of time. So, the present study aims for propagating continuous cell line of vero cell on microcarrier beads for increase the yield of PPR virus vaccine.

2. Materials and methods

2.1. Cell line and Virus

African green monkey kidney (Vero) cell line was propagated on minimum essential medium (MEM) supplemented with 10% fetal calf serum was used.

The PPR vaccinal strain used was PPR virus Nigeria 75/1 which obtained from Centre de Cooperation international en Recherche Agronomique pour le Development (CIRAD) France it was used as seed virus to prepare the live attenuated PPR cell culture vaccine at Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt. The virus titre was 106 TCTD 50 per mL on vero cells

2.2. Systems used in tissue culture :

Cell culture were maintained as monolayers in 175 cm2 Roux flask.

Cell culture were maintained as roller of 530 cm2.

Cytodex-3 Miccrcomer (Bomstein, et al., 1980)

2.3. Microcarriers cultures

Cytodex -3 microcarriers (Solo HILL Engineering Inc. USA) Cytodex 3 microcarriers consist a surface of denatured collagen covalently bound to a matrix of cross-linked dextran. The amount of denatured collagen bound to the microcarrier matrix is approx.60µg/cm2 and results in maximum cell yields. The denatured collagen (MW 60,000-200,000) is derived from pig skin type I collagen which has been extracted and denatured by acid treatment, concentrated and purified by an ion exchange step and steam sterilized before being coupled to the microcarrier matrix these microcarrier combine the advantages of collagen coated culture surfaces with the advantages and possibilities of microcarrier culture cytodex 3 microcarriers can also be used according to the manufacturers instructions and there are many types of it as Cytodex 1, 2, 3 and collagen but in our study we used Cytodex 3 as it used with vero cell and prepared ad follow:

Briefly transfer 250mg of microcarriers beads into celstir spinner flask (Wheaton Science Products, USA) consists of a borosilicate glass flask with an integral cap and magnetic impeller assembly. Add 30ml of de-ionized water before autoclaving at 121°C for at least 30 minutes; decant the autoclaved liquid through pipette aid.

Microcarriers cultures were established by inoculating cells (2x 105cells/ml) into growth medium containing 250 mg microcarriers beads /1000mL. The cultures were maintained in clusters in incubator equipped with a stir plate set at 50 rpm.

2.4. Culture sample:

Cell culture samples (1ml) were obtained daily into Eppendorf tubes for staining and counting by haemocytometer grade and using the trypsin-EDTA solution to make detached the cell from beads.

2.5. Inoculation and propagation of PPRV on cell culture

Cell cultures were infected by removing 90% of the medium after settled microcarriers through side-arm of vessel, followed by addition of 50ml of PPR vaccine virus at a multiplicity of infection "MOI" (0.001 TCTD50). PPR attenuated virus strain 75/1 was kindly supplied by Dr. Adam Diallo.
(CIRAD-EMVT) and titrated before use (OIE, 2000). The cultures were readjusted to their original volume by adding MEM and during viral infection the culture stirred intermittently at 50 rpm. Culture samples were taken at regular intervals (24, 48, 72, 96, 120 and 144 hours post sell infection). Each sample was freeze and thawed (x3) to release of intracellular vims. The yielded virus was titrated using the microliter technique (OIE, 2000). The used multiplicity of infection in this study was based on the protocol of PPR vaccine production in the Center of Veterinary vaccine, Kingdom of Saudi Arabia, Riyadh.

2.6. Virus titration

Infectivity titration of pprv:

Virus titration was conducted using infectivity method according to. Serial 10-fold dilutions in Hank's balanced salt solution (HBSS) were prepared from each virus. 0.1 ml of each virus dilution inoculated into tissue culture tubes and incubated at 37°C for two hrs to allow virus adsorption with intermittent tilting of tubes every 10 minutes. After incubation for adsorption, each tube was inoculated with two ml of maintenance media and the medium was changed every 3 days. The tubes were incubated at 37°C for 14 days and the culture was examined daily for the development of cytopathic effect. The titer of the virus was expressed as TCID50/ml using the formula of (Reed and Muench, 1938).

2.7. Quality control of the PPR vaccine:

2.7.1. Sterility test:

a) Sterility for bacterial and fungal contamination:

The prepared live attenuated PPR vaccine was cultured on different synthetic media for detection of bacterial and fungal growth. It was found that the vaccine was sterile as it was free from any bacterial, fungal and mycoplasma contaminants (OIE, 2008).

b) Sterility for other viruses:

There was no cytopathic effect 'CPE' of the inoculated cell line with mixture of PPRV with its hyperimmune sera, which indicated that the vaccines were free from other viruses (OIE, 2008).

2.7.2. Safety test:

It was performed in accordance with OIE (2008) in goats where, nine goats of eight to twelve months old were used for each prepared live attenuated PPRV vaccine supporting on row, roller, microcarrier were inoculated subcutaneously in the neck region with 5 log 10 TCID50/ dose/ head. Another two goats were injected with equal amount of the physiological saline and kept as a control non-vaccinated group. All animals kept under clinical for two weeks before injection and record the rectal temperature for them. They were kept under clinical after injection for 28 days.

2.7.3. Potency Test:

Twelve local breed female goats of nine to twelve months old were used. These goats were apparently healthy and free from antibodies against PPR virus as proved by using serum neutralization test. The goats were used to compare the potency of the different stabilized vaccine by dividing into four groups as follow:

Group I: Each of three goats was vaccinated subcutaneously with 1ml of 2 log10 TCID50 live attenuated PPR virus vaccines supporting on row bottles.

Group II: Each of three goats was vaccinated subcutaneously with 1ml of 2 log10 TCID50 live attenuated PPR virus vaccines with roller bottles.

Group III: Each of three goats was vaccinated subcutaneously with 1ml of 2 log10 TCID50 live attenuated PPR virus vaccines with cytodex-3 Micro carrier.

Group IV: three Goats were left as non-vaccinated controls. Each of these Goats was subcutaneously injected with physiological saline and was left as control.

Goats were housed in mosquito proof isolated stable and daily clinical Serum samples were
collected from vaccinated and unvaccinated goats on the day of vaccination (zero day), then weekly till 28th day post vaccination for serological investigation. The vaccinated and unvaccinated control goats were observed clinically during the experiment for any clinical abnormalities during the experiment. The body temperature of the goats was recorded daily before and after vaccination for one week.

2.8. Serum samples:
All sera were collected from groups I, II, III, IV, on the day of vaccination (zero day), then weekly till 28th day post vaccination. The sera were stored at -20°C and inactivated at 56°C for 30 minutes before being examined by the Serum Neutralization Test (SNT) (OIE, 2004).

2.9. Serum neutralization test (SNT) OIE (2004):
This test was carried out both qualitatively to screen goat sera samples to prove their susceptibility, as well as quantitatively to estimate the neutralizing antibody titers in goat sera, acquired through PPRV vaccine inoculations. The test was carried out in 96-well microtitre plates; Vero cell suspensions were prepared at 600,000/ml, as well as a complete culture medium.

3. RESULTS
The Table (1) demonstrated that the growth rate of vero cell with 175 cm² is \(1.75 \times 10^7\) and in the Roller with 530 cm² is \(5.3 \times 10^7\) and in the cytodex-3 is \(115 \times 10^6\).

The cytodex 3 microcarrier produce 7 log virus titers higher than the row and 6 log viruses than in roller.

That vaccine production capacity of 250 mg Cytodex 3 in 250m media is corresponding to that of 8 roux flask and 4 roller bottles.

In table (2), The differences in neutralizing serum antibody titres through the vaccine produced from three systems are insignificant.

** Geometric mean serum neutralizing antibody titre expressed as the reciprocal of the least serum dilution that inhibited the appearance of cpe produced by 100 TCID 50 of PPRV / 0.1ml on vero cells.

In table (3), The differences in neutralizing serum antibody titres through the vaccine produced from three systems are in significant.

** Geometric mean serum neutralizing antibody titre expressed as the reciprocal of the least serum dilution that inhibited the appearance of cpe produced by 100 TCID 50 of PPRV / 0.1ml on vero cells.

<table>
<thead>
<tr>
<th>System No.</th>
<th>Vero cell culture system unit (steered)</th>
<th>Cell growth surface area / unit (cm²)</th>
<th>Media volume / unit (mL)</th>
<th>Average cell yield from a 100 % confluent culture</th>
<th>PPRV-harvest / unit (mL)</th>
<th>Formulated vaccine volume / unit (mL)</th>
<th>Log_{10} TCID_{50} title / mL of fluid vaccine</th>
<th>*No. of field vaccine doses produced / unit (3log_{10} TCID_{50})</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Stationary (Roux Flask) Rolling bottle</td>
<td>175</td>
<td>75</td>
<td>1.75 x 10^7</td>
<td>75</td>
<td>150</td>
<td>5.0</td>
<td>15000</td>
</tr>
<tr>
<td>2</td>
<td>Rolling (Roller bottle)</td>
<td>530</td>
<td>125</td>
<td>5.3 x 10^7</td>
<td>125</td>
<td>250</td>
<td>6.0</td>
<td>30000</td>
</tr>
<tr>
<td>3</td>
<td>Micro carriers of cytodex 3 (spinner flask)</td>
<td>1150/250 mg /250mg</td>
<td>115x10^6 /250mg</td>
<td>250</td>
<td>500</td>
<td>12</td>
<td>120000</td>
<td></td>
</tr>
</tbody>
</table>
**Table 2.** Results of potency testing of PPRV – vaccine produced through three different vero cell culture systems – in goats.

<table>
<thead>
<tr>
<th>Vero cell culture system / PPRV production</th>
<th>No. of goats vaccinated</th>
<th>PPRV-vaccine SC/dose / head</th>
<th>Serum/PPRV-neutralizing antibody titres</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stationary (Roux)</td>
<td>3</td>
<td>0</td>
<td><strong>0</strong> 2 8 16 16</td>
</tr>
<tr>
<td>Roller</td>
<td>3</td>
<td>2 log₁₀</td>
<td>0 4 16 32 32</td>
</tr>
<tr>
<td>Micro carrier</td>
<td>3</td>
<td>TCID₅₀</td>
<td>0 4 32 32 32</td>
</tr>
<tr>
<td>Unvaccinated control</td>
<td>3</td>
<td>Placebo</td>
<td>0 0 0 0 0</td>
</tr>
</tbody>
</table>

Day post vaccination

**Table 3.** Results of Safety testing of PPRV – vaccine produced through three different vero cell culture systems – in goats.

<table>
<thead>
<tr>
<th>Vero cell culture system / PPRV production</th>
<th>No. of goats vaccinated</th>
<th>PPRV-vaccine SC/dose / head</th>
<th>Serum/PPRV-neutralizing antibody titres</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stationary (Roux)</td>
<td>3</td>
<td>0</td>
<td><strong>0</strong> 4 8 16 16</td>
</tr>
<tr>
<td>Roller</td>
<td>3</td>
<td>5 log₁₀</td>
<td>0 8 16 32 32</td>
</tr>
<tr>
<td>Micro carrier</td>
<td>3</td>
<td>TCID₅₀</td>
<td>0 8 16 32 32</td>
</tr>
<tr>
<td>Unvaccinated control</td>
<td>3</td>
<td>Placebo</td>
<td>0 0 0 0 0</td>
</tr>
</tbody>
</table>
4. DISCUSSION
In this study, we have tried to change the routine method and substitute new trend for preparation of viral animal vaccine as sheep, goat; rinderpest disease to increase yield cell and vaccine production and consequently reduction cost of raw material as growth media, serum and trypsin. After six days of incubation periods as in the table (1) demonstrated that growth rate of vero cell culture in stationary flask (175cm²) was $1.75 \times 10^7$ and the growth rate of vero cell culture in roller bottles was $5.3 \times 10^7$ and cell count obtained by microcarriers was $115 \times 10^6$/250ml this observation could be attributed to the broader culture surface provided by the microcarriers than that provide by the fixed area of stationary flasks and roller bottles (Uma and Bandyophayay, 1994), (Montagnon, et al., 1981)
Concerning titer of PPR virus obtained on Vero cells it was found that roux flask (175cm²) yielded virus titer was $(10^5)$ and the virus titer of roller bottles was $(10^6)$ while higher virus titer was obtained by the same cell grown on cytodex-3 microcarriers was $(10^{12})$. These finding could be also attributed to the greater number of infected cells in case of microcarriers than in case of stationary flasks and roller bottles. Such significant higher titer obtained by microcarriers culture when compared with stationary culture (seven log) (Uma and Bandyophayay, 1994).
Also (Mohan, et al., 2009) stated that the microcarrier culture produced seven log high titer of PPR virus than the stationary culture and six log high titer of PPR virus than of the roller bottles. They attributed the induction of higher virus yield to a regime of intermittent low speed stirring during infection of microcarriers culture, to ensure penetration of the virus into the cells, Although continuous stirring has been reported for infection of other
virus such as polio and rabies (Rourou, et al., 2007 and Berry, et al., 1999). Higher virus titer obtained may be (Mohan et al., 2009) due to low multiplicity of infection (MOI) where they used (0.005 TCID\textsubscript{50}/cell) and it has been observed that multiplication of PPR virus with a low MOI resulted in high titer, but it may takes time to get a cytopathic effect (CPE) in vaccine production process, so in this study we used MOI (0.001 TCID\textsubscript{50}) as recommended by (OIE, 2004) indicating that two critical parameters affect the titer of virus in cell culture, cell density and the MOT of virus. PPR serum neutralizing antibodies in goats were induced by the 7\textsuperscript{th} DPV with live attenuated PPR virus vaccines supported on row, roller and microcarrier systems and higher mean neutralizing PPR antibody titers was induced by microcarrier systems. The immune response of PPR vaccine produced through three systems were approximately the same and the difference were in non-significant (Rossiter et al., 1982) as in the fig. (2-3).

5. Conclusion
These results administrate further insights into the applying microcarriers cell culture technology to produce PPR attenuated vaccine providing powerful alternatives to the older methods of vaccine manufacturing that the main of the study is to prepare three different patches of the vaccines through the three system and comparable the efficiency of three system, that the obtain result shows that the virus culture on microcarrier give high titer 12 log TCTD 50.

6. REFERENCES


